New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 12, 2012
10:00 EDTCAT, PBR, BMY, VNO, VRTX, STRA, NKTR, KRC, JNJ, JCP, GRMN, IQNT, HESOn The Fly: Analyst Downgrade Summary
Today's noteworthy downgrades include: Caterpillar (CAT) downgraded to Neutral from Overweight at JPMorgan... Garmin (GRMN) downgraded to Sell from Neutral at Goldman... Inteliquent (IQNT) downgraded to Underweight from Equal Weight at Morgan Stanley... J.C. Penney (JCP) downgraded to Underperform from Neutral at Credit Suisse... Johnson & Johnson (JNJ) downgraded to Hold from Buy at Jefferies... Kilroy Realty (KRC) downgraded to Neutral from Buy at BofA/Merrill... Nektar (NKTR) downgraded to Hold from Buy at Jefferies... Strayer Education (STRA) downgraded to Neutral from Overweight at JPMorgan... Vertex (VRTX) downgraded to Neutral from Outperform at Credit Suisse... Vornado (VNO) downgraded to Neutral from Buy at BofA/Merrill... Bristol-Meyers (BMY) downgraded to Market Perform from Outperform at BMO Capital... Petrobras (PBR) downgraded to Neutral from Buy at BofA/Merrill... Hess Corp. (HES) downgraded to Market Perform from Outperform at Howard Weil.
News For CAT;IQNT;GRMN;JCP;JNJ;KRC;NKTR;STRA;VRTX;VNO;BMY;PBR;HES From The Last 14 Days
Check below for free stories on CAT;IQNT;GRMN;JCP;JNJ;KRC;NKTR;STRA;VRTX;VNO;BMY;PBR;HES the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | all recent news | >>
July 29, 2014
16:23 EDTVRTXVertex reports Q2 EPS (68c), consensus (72c)
Reports Q2 revenue $138M, consensus $132.06M.
15:53 EDTHES, GRMNNotable companies reporting before tomorrow's open
Subscribe for More Information
15:53 EDTVRTXNotable companies reporting after market close
Subscribe for More Information
14:01 EDTGRMNGarmin technical notes ahead of results
Subscribe for More Information
13:59 EDTGRMNGarmin August volatility increases into Q2
Garmin August call option implied volatility is at 41, October is at 27, January is at 24; compared to its 26-week average of 27, according to Track Data, suggesting large near term price movement into the expected release of Q2 results on July 30.
13:25 EDTKRCKilroy Realty sees FY14 FFO $2.70-$2.79 , consensus $2.74
Subscribe for More Information
10:37 EDTSTRAStrayer upgraded to Hold from Sell at Deutsche Bank
09:01 EDTCATCaterpillar board announces $2.5B accelerated stock repurchase
Pursuant to the terms of the accelerated stock repurchase agreements, Caterpillar has agreed to repurchase a total of $2.5 billion of its common stock from Société Générale, with an immediate delivery of approximately 22 million shares based on current market prices.
08:50 EDTJNJHarris & Harris invests in Accelerator Corporation
Subscribe for More Information
08:00 EDTGRMNGarmin should be bought on any weakness after results, says Oppenheimer
Subscribe for More Information
07:09 EDTBMYBristol-Myers, Pfizer granted EU approval for Eliquis for treatment of DVT, PE
Subscribe for More Information
July 28, 2014
18:09 EDTKRCKilroy Realty reports Q2 FFO 72c, consensus 70c
Subscribe for More Information
13:20 EDTJNJPharmacyclics granted regular approval for Imbruvica
Subscribe for More Information
12:26 EDTJNJPharmacyclics off lows, turns positive after FDA expands Imbruvica indication
Subscribe for More Information
12:24 EDTJNJFDA expands approved use of Imbruvica for chronic lymphocytic leukemia
The U.S. Food and Drug Administration today expanded the approved use of Imbruvica to treat patients with chronic lymphocytic leukemia who carry a deletion in chromosome 17, which is associated with poor responses to standard treatment for CLL. Imbruvica received a breakthrough therapy designation for this use. The FDA is also approving new labeling to reflect that Imbruvica’s clinical benefit in treating CLL has been verified. Imbruvica’s new use is being approved more than two months ahead of the product’s prescription drug user fee goal date of Oct. 7, the date the FDA was scheduled to complete review of the drug application. Imbruvica also received accelerated approval in November 2013 for the treatment of patients with mantle cell lymphoma who have received at least one prior therapy. Clinical studies to verify and describe Imbruvica’s clinical benefit in mantle cell lymphoma are ongoing. Imbruvica is being jointly developed and commercialized in the United States by Pharmacyclics (PCYC) and Janssen Biotech (JNJ).
11:49 EDTPBRStocks with call strike movement; PBR QIHU
Petrobras (PBR) November 19 call option implied volatility increased 4% to 50, Qihoo 360 (QIHU) December 115 call option implied volatility decreased 2% to 49 according to IVolatility.
07:43 EDTNKTRNektar shares offer favorable risk/reward, says Jefferies
Subscribe for More Information
06:32 EDTJNJJ&J dispute with Boston Scientific looks set to go to trial, NY Times says
Subscribe for More Information
July 25, 2014
10:02 EDTCATOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
10:02 EDTPBROn The Fly: Analyst Upgrade Summary
Subscribe for More Information
1 | 2 | 3 | 4 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use